Prescription rate and treatment patterns for allergic rhinitis from 2010 to 2018 in South Korea: a retrospective study

Jaemin Son¹, Eun-San Kim², Hee-seung Choi³, In-Hyuk Ha², Donghyo Lee⁴* and Yoon Jae Lee²* ©

Abstract

Background: There has been little investigation on how guidelines for allergic rhinitis (AR) treatment are applied in current clinical practice. We aimed to analyze prescription trends and patterns for AR treatment according to patient characteristics over a 9-year period in Korea.

Methods: We used cross-sectional data from the Korean Health Insurance Review & Assessment Service National Patient Sample from 2010 to 2018. We analyzed 1,719,194 patients with AR as the principal diagnosis. Prescription rates of antihistamines, steroids, and other drugs; combination prescriptions; and first-choice prescriptions were analyzed.

Results: The prescription rate of first-generation antihistamines decreased over the years (2010: 29.13; 2018: 23.41). By contrast, the prescription rate of systemic steroids (2010: 23.60; 2018: 28.70), nasal steroids (2010: 9.70; 2018: 14.67), and leukotriene receptor antagonists (LTRAs) (2010: 11.13; 2018: 26.56) increased. The prescription rate of steroids was lower in patients aged 0–5 years and ≥65 years than in other age groups and that of LTRAs was the highest in patients aged 0–5 years. The rate of combination prescribing antihistamines and nasal steroids increased (2010: 7.99; 2018: 12.09). The rate of first-choice prescriptions with antihistamines and nasal steroids also increased (2010: 4.72; 2018: 7.24).

Conclusions: The results confirmed a decrease in antihistamine prescriptions, especially with first-generation, and an increase in steroid and LTRA prescriptions in patients with AR in Korea. Regarding prescription patterns, steroids were increasingly prescribed in combination with antihistamines. However, the trend was opposite in the 0–5 years and ≥65 years groups.

Keywords: Allergic rhinitis, Medication, Prescription pattern, Prescription trend

Background

Allergic rhinitis (AR) is a common disease worldwide [1]. In particular, pediatric AR has a high incidence rate, with a global prevalence of approximately 14% at the ages of 13 and 14 years [2]. In 2018, 16.7% of adults in South Korea were diagnosed with AR [3]. The disease reduces workers’ productivity [4] and negatively affects the quality of sleep [5] and quality of life [6]. It can also cause complications such as sinusitis or otitis media [7].

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines recommend second-generation antihistamines and nasal steroids as medications for AR. Leukotriene receptor antagonists (LTRAs) are also recommended [8]. AR-related clinical guidelines developed in South Korea recommend the use of second-generation antihistamines,
LTRAs, and nasal steroids [9]. However, studies have mainly focused on the treatment efficacy through randomized controlled trials, and few studies have assessed how different medications are used in clinical practice [10–13]. Ghouri N, et al. [10] studied prescription of antihistamines and drugs used in nasal allergy from 2001 to 2005 in the United Kingdom (UK). However, guidelines have since changed [8] and the types of medications have varied. Subsequently, a systematic survey of physicians was conducted in Italy [12] and the UK [11]. There were differences in prescription patterns depending on the region, indicating that research on prescription patterns in Korea is also necessary. Although a survey on prescription patterns was conducted with physicians in Korea [13], the samples used in that study were limited in terms of representing the entire Korean population due to the nature of the study design. In addition, it is difficult to analyze long-term trends from previous studies due to the nature of cross-sectional studies, and it was difficult to identify prescription patterns according to patient characteristics. Therefore, this study was aimed at analyzing medication prescription trends for AR and prescription patterns based on patient characteristics using data from a nationwide insurance claims database over a span of 9 years.

Methods

Data

Data from the Korean Health Insurance Review & Assessment Service National Patient Sample (HIRA-NPS) from 2010 to 2018 were used in this study. HIRA-NPS consists of cross-sectional data constructed using stratified sampling of 3% of all patients who used medical institutional services each year according to sex and age group (5-year interval). Data on approximately 1.45 million patients are extracted every year, and the data can be accessed through the de-identification of personally identifiable information. HIRA-NPS is a single national health insurance database that represents the South Korean population, and the data therein have high validity in terms of representativeness [14]. The database includes demographic characteristics such as patient sex and age, diagnosis code, medical procedures provided to patients by medical institutions, and details of medication and associated costs.

Population and characteristics

The definition of AR was set according to the Korean Standard Classification of Diseases, 7th Revision. Therefore, AR patients were defined as patients for whom AR was recorded as the principal diagnosis (codes: J30, J301, J302, J303, and J304) at least once per year. The patient characteristics extracted from the data included sex, age, and comorbidity. In terms of age, patients were classified into six age groups: 0–5 years, 6–12 years, 13–19 years, 20–39 years, 40–64 years, and ≥ 65 years. To determine the comorbidity status of other allergic diseases, if the disease was recorded as a principal or secondary diagnosis at least once in a given year, the patient was considered to have the disease. Types of comorbidities included allergic asthma (code J450) and allergic dermatitis (codes L20, L208, L2080, L2088, and L209).

Measures

For the analysis of the type of medication prescribed, the major drugs for AR treatment were selected from literature, like the ARIA guidelines [8, 15–17]. Accordingly, antihistamines, steroids, LTRAs, systemic decongestants, and cough and cold preparations were included in the analysis. Antihistamines were divided into first- and second-generations with total prescriptions; steroids were also divided into total, nasal, and systemic steroids. Medication types were defined according to the Anatomical Therapeutic Chemical Classification System (see Additional file 1: Table S1).

Next, 1-year episodes in patients with AR were analyzed to examine patients’ prescription patterns. First, prescription combination patterns were analyzed. Cases were classified as prescription of first-generation antihistamines only, second-generation antihistamines only, antihistamines and nasal steroids, or nasal steroids only. Furthermore, to examine the first-choice prescription for AR patients, we investigated patient prescriptions for the initial episodes. Cases were classified as prescription of antihistamines only, nasal steroids only, or antihistamines and nasal steroids. The prescription of LTRAs, decongestants, and cough and cold preparations was not considered in the first-choice prescription analysis.

Analysis

Basic patient characteristics included the number of patients (n) and percentages, and a chi-square test was performed to analyze differences in characteristics by year. Annual prescription rates were investigated by medication type. Furthermore, the prescription rate was presented as per 100 patients with AR and was sex- and age-standardized according to the population composition in 2010. To determine the trend in prescription rate for each year, the p trend was analyzed by linear regression analysis, considering the year as a continuous variable. Statistical significance was set at P-value ≤ 0.05.

A subgroup analysis according to patient characteristics was performed with age (0–5, 6–12, 13–19, 20–39, 40–64, and ≥ 65 years) and the comorbidity status of allergic asthma and allergic dermatitis. The age groups of 0–5 years and ≥ 65 years had the most pronounced
differences in pattern from the total population. The results for other subgroups are presented in Additional file 1: Table S2a–h.

**Results**

From 2010 to 2018, a total of 1,719,194 AR patients were included in the study, of which 794,726 (46.22%) were male and 924,468 (53.77%) were female patients. The basic characteristics of patients for each year are shown in Additional file 1: Table S3. The number of AR patients by year showed a year-on-year increase (n, 2010: 167,524; 2018: 213,420). The proportion of patients aged 0–5 years increased (percentage, 2010: 14.0%; 2018: 17.5%, \( P < 0.001 \)), while that of patients aged 13–19 years decreased (percentage, 2010: 10.5%; 2018: 8.1%, \( P < 0.001 \)). Furthermore, the proportion of patients with allergic asthma and allergic dermatitis increased in general (percentage of allergic asthma patients, 2010: 8.1%; 2018: 10.3%, \( P < 0.001 \); percentage of allergic dermatitis patients, 2010: 9.3%; 2018: 10.4%, \( P < 0.001 \)).

The prescription rate was generally higher for second-generation antihistamines than for first-generation antihistamines (First-generation antihistamine prescription rate, 2010: 29.13; 2018: 23.41, \( P < 0.001 \); Second-generation antihistamine prescription rate, 2010: 73.56; 2018: 72.02, \( P = 0.010 \); Table 1). Moreover, the prescription rate for first-generation antihistamines showed a more steeply decreasing trend (prescription rate, 2010: 29.13; 2018: 23.41, \( P < 0.001 \)) than first-generation antihistamines. In particular, the prescription rate for first-generation antihistamines in the age group \( \geq 65 \) years markedly decreased (prescription rate, 2010: 41.15; 2018: 33.39, \( P < 0.001 \); Fig. 1a).

The prescription rate was generally higher for systemic steroids than for nasal steroids and showed an increasing trend (Nasal steroids prescription rate, 2010: 9.70; 2018: 14.67, \( P = 0.008 \); Systemic steroids prescription rate, 2010: 23.60; 2018: 28.70, \( P < 0.001 \)). In particular, the prescription rate for nasal steroids has increased significantly since 2015 (prescription rate, 2015: 10.07; 2018: 14.67). The prescription rate for total steroids was the lowest in patients aged 0–5 and \( \geq 65 \) years; however, the rate increased over time for patients aged \( \geq 65 \) years (0–5-year prescription rate, 2010: 16.87; 2018: 19.88; \( P = 0.072 \); \( \geq 65 \) years prescription rate, 2010: 26.76; 2018: 34.64; \( P < 0.001 \)) (Fig. 1b). The steroid prescription rate in asthma patients was higher than that in atopic dermatitis patients, and the prescription rate increased in both groups (prescription rate for asthma, 2010: 30.87; 2018: 37.30; \( P = 0.001 \); prescription rate for atopic dermatitis, 2010: 26.70; 2018: 32.96; \( P = 0.002 \)) (see Additional file 1: Table S2g–h).

| Table 1 | Rates of prescription and pattern by year |
|---------|------------------------------------------|
| **Year** | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | Beta | \( P \)-value |
| Antihistamines | | | | | | | | | | | 0.001 |
| Total antihistamines | 84.47 | 84.44 | 84.05 | 83.87 | 81.81 | 80.77 | 80.70 | 80.53 | 79.75 | -0.67 | < 0.001 |
| First generation | 29.13 | 29.25 | 29.12 | 28.78 | 27.27 | 26.25 | 25.70 | 24.56 | 23.41 | -0.77 | < 0.001 |
| Second generation | 73.56 | 73.89 | 73.78 | 73.97 | 72.20 | 71.77 | 72.20 | 72.46 | 72.02 | -0.26 | 0.010 |
| Steroids | | | | | | | | | | | 0.008 |
| Total steroids | 30.43 | 32.17 | 32.09 | 33.38 | 32.90 | 33.28 | 33.63 | 34.17 | 35.00 | 0.95 | < 0.001 |
| Nasal steroids | 9.70 | 10.51 | 10.01 | 10.54 | 10.09 | 10.07 | 10.90 | 15.08 | 14.67 | 0.61 | 0.008 |
| Systemic steroids | 23.60 | 25.04 | 25.25 | 26.24 | 26.12 | 26.94 | 27.36 | 28.21 | 28.70 | 0.58 | < 0.001 |
| Other drugs | | | | | | | | | | | 0.002 |
| Leukotriene antagonists | 11.13 | 12.88 | 17.58 | 19.86 | 21.85 | 22.98 | 21.08 | 19.91 | 26.56 | 1.55 | 0.002 |
| Systemic decongestants | 51.97 | 53.05 | 53.37 | 52.46 | 54.91 | 55.32 | 56.36 | 57.13 | 56.34 | 0.68 | < 0.001 |
| Cough and cold preparations | 58.79 | 56.71 | 56.43 | 55.99 | 57.23 | 56.77 | 57.36 | 57.31 | 58.17 | 0.03 | 0.791 |
| Prescription combination pattern | | | | | | | | | | | 0.001 |
| First-generation antihistamines only | 10.50 | 10.08 | 9.83 | 9.43 | 9.43 | 9.19 | 8.60 | 8.12 | 7.59 | 7.28 | -0.41 | < 0.001 |
| Second-generation antihistamines only | 49.46 | 48.96 | 49.04 | 48.86 | 48.53 | 48.52 | 47.71 | 46.57 | 47.14 | -0.32 | < 0.001 |
| Antihistamines and nasal steroids | 7.99 | 8.74 | 8.28 | 8.27 | 8.32 | 8.28 | 9.83 | 12.50 | 12.09 | 0.51 | 0.009 |
| Nasal steroids only | 1.71 | 1.77 | 1.73 | 1.82 | 1.77 | 1.79 | 2.06 | 2.58 | 2.58 | 0.11 | 0.004 |
| First-choice prescription | | | | | | | | | | | 0.001 |
| Antihistamines only | 76.33 | 75.76 | 75.27 | 74.68 | 72.35 | 71.10 | 70.06 | 68.04 | 67.27 | -1.22 | < 0.001 |
| Nasal steroids only | 1.94 | 1.99 | 1.93 | 2.06 | 1.95 | 1.96 | 2.21 | 2.92 | 2.90 | 0.12 | 0.011 |
| Antihistamines and nasal steroids | 4.72 | 5.15 | 4.88 | 5.22 | 4.97 | 4.94 | 5.69 | 7.42 | 7.24 | 0.30 | 0.008 |

Prescription and pattern rates per 100 patients are presented by year. Rates were sex- and age-standardized according to the population composition of 2010.
The prescription rate of LTRAs has increased, with the largest rate of increase in 2018 (prescription rate, 2010: 11.13; 2018: 26.56; \( P < 0.001 \)). The prescription rate for systemic decongestants increased (prescription rate, 2010: 51.97; 2018: 56.34; \( P < 0.001 \)), while that for cough and cold preparations did not show a significant change (prescription rate, 2010: 58.79; 2018: 58.17; \( P = 0.791 \)). The prescription rate of LTRAs, systemic decongestants,
and cough and cold preparations were the highest in patients aged 0–5 years and showed a decreasing trend with age. Furthermore, the prescription rate was higher for cough and cold preparations than for systemic decongestants in patients aged ≥65 years. The increase in the prescription rate of LTRAs was the highest in the age group 0–5 years (prescription rate, 2010: 19.05; 2018: 50.48; P < 0.001) (Fig. 1c). Also, the largest difference in prescription rate between allergic asthma and atopic dermatitis patients and total population was LTRAs (prescription rate in allergic asthma patient, 2010: 16.69; 2018: 41.34; P < 0.001; prescription rate in atopic dermatitis patient, 2010: 26.25; 2018: 45.91; P < 0.001) (see Additional file 1: Table S2g–h).

The prescription rate of “second-generation antihistamines only” was the highest overall; however, it showed a decreasing trend (prescription rate, 2010: 49.46; 2018: 47.14, P < 0.001). By contrast, the prescription rate of “antihistamines and nasal steroids” (prescription rate, 2010: 7.99; 2018: 12.09, P = 0.009) and “nasal steroids only” showed an increasing trend (prescription rate, 2010: 1.71; 2018: 2.58, P = 0.004). The trend was generally consistent in all age groups. Nevertheless, the prescription rate of “antihistamines and nasal steroids” and “nasal steroids only” was lower in the age groups 0–5 years and ≥65 years than in the other groups (Fig. 2a).

“Antihistamines only” was the most often used first-choice prescription category; however, the corresponding prescription rate decreased over time (prescription rate, 2010: 76.33; 2018: 67.27, P < 0.001). By contrast, the prescription rate of combination prescription of antihistamines and nasal steroids (prescription rate, 2010: 4.72; 2018: 7.24, P = 0.008) and “nasal steroids only” (prescription rate, 2010: 1.94; 2018: 2.90, P = 0.011) increased. The

**Fig. 2** Rates of prescription pattern by year. The prescription rate per 100 patients is presented by year: **a** Combination patterns; **b** First-choice prescription. An episode refers to all medical records of the patient receiving allergic rhinitis treatment for 1 year. Rates were sex- and age-standardized according to the population composition of 2010.
trend was consistent in most age groups; nevertheless, the prescription rate of combination prescription of antihistamines and nasal steroids (prescription rate, 2010: 1.54; 2018: 1.90, \( P = 0.548 \)) and “nasal steroids only” (prescription rate, 2010: 0.98; 2018: 1.22, \( P = 0.728 \)) was the lowest in patients aged 0–5 years, and there was no significant increase in these rates (Fig. 2b).

**Discussion**

In this study, the trends and patterns of medication prescriptions for patients with AR were analyzed for the period from 2010 to 2018. The results confirmed that the prescription of antihistamines, particularly first-generation antihistamines, decreased while the prescription of steroids and LTRAs increased. The prescriptions of “antihistamines only” decreased, whereas the prescription rate of “antihistamine and nasal steroids” and “nasal steroids only” increased. However, the trends differed depending on patient characteristics. In particular, the increase in the rate of steroid prescription was relatively low in patients aged 0–5 years and ≥ 65 years. Furthermore, for these age groups, the rate of steroid prescription was also relatively low in combination prescriptions and first-choice prescriptions.

Some results of this study are consistent with a previously conducted survey in Korea. Antihistamines were the first-choice medication. Furthermore, pediatricians have reported lower prescription rates of combinations of antihistamines and nasal steroids and higher prescription rates of LTRAs than the prescription rates reported by physicians of other specialties [13]. This trend was also confirmed in a subgroup analysis of our study. However, the previous study showed that the combination of nasal steroids and antihistamines was the most prescribed. By contrast, in the present study, the prescription rate of second-generation antihistamines alone was the highest, although it showed a decreasing trend. This variance may be attributed to difference in study subjects. In the present study, medical records of all relevant patients were analyzed, and thus, patients with mild AR were also included in the analysis. By contrast, as the previous study performed a survey that relied upon the physician’s memory, only prescription patterns for patients with frequent visits may have been reported.

In particular, a remarkable decrease was noted in the prescription rate of first-generation antihistamines, which could be attributed to the superiority of second-generation antihistamines. The latter have a faster and longer-lasting effect than the first-generation antihistamines [18], and are safer with only a slight sedative effect [19]. Furthermore, second-generation antihistamines have been reported to be safer than first-generation antihistamines even when used in combination with other drugs [20]. Also, ARIA and standard guidelines of the Korean Academy of Asthma, Allergy, and Clinical Immunology recommend the use of second-generation antihistamines [8, 9].

The use of nasal steroids has been increasing. Moreover, the combination of nasal steroids and antihistamines has shown the largest rate of prescription increase. ARIA and the standard guidelines of the Korean Academy of Asthma, Allergy, and Clinical Immunology state that nasal steroids are more effective than antihistamines in relieving nasal blockage [8, 9]. These results, and changes in the guidelines, are thought to have had some effect on the prescription patterns. However, compared with the extensive use of nasal steroids in other countries [11, 12], the use of nasal steroids in Korea has remained at around 10–20%.

Rather, it should be noted that the use of systemic steroids was the highest among steroids in Korea, and the use of systemic steroids has shown an increasing trend. Prescription rates for systemic steroids were also the highest for the age groups 0–5 years and ≥ 65 years. Systemic steroids are only recommended for patients with very severe and therapy-resistant symptoms due to concerns of adverse events [21]. This pattern was not identified in other countries [11, 12], and was not reported in the previous survey in Korea [13]. Further studies are required to investigate the characteristics and prognosis of patients prescribed these drugs.

We observed increased prescription of LTRAs. These drugs alleviate nasal and ocular symptoms [22] and are more effective in combination therapy with antihistamines and steroids [23–25]. In particular, the safety of LTRAs demonstrated in children [26, 27] may have resulted in the increased prescription of LTRAs in patients aged 0–5 years. Based on these results, the reimbursement criteria for LTRAs were expanded in Korea at the end of 2017. Before the amendment, reimbursement was only possible when there was no improvement with antihistamine treatment, but now LTRAs are reimbursed even when prescribed as a first-line treatment [28]. The increase in LTRAs prescriptions in 2018 is thought to have reflected these changes.

The prescription rates for allergic asthma and atopic dermatitis patients were similar to the total allergic rhinitis patients, except that the prescription rate of LTRAs was higher for allergic asthma and atopic dermatitis patients. LTRAs are effective for controlling asthma symptoms [29]. Therefore, physicians might have prescribed the LTRAs for allergic rhinitis patients with asthma symptoms. Although the evidence of using LTRAs for atopic dermatitis is limited [30], the high prescription rates might be due to the younger age of atopic dermatitis patients (data not presented). The
prescription rates of other medications should be interpreted with caution. Depending on patient’s severity, other medications, especially steroids, might have been prescribed with allergic asthma or atopic dermatitis as primary diagnosis, not allergic rhinitis. If the patient had been prescribed steroids with allergic asthma or atopic dermatitis as primary diagnosis closely before the patient visited for allergic rhinitis, the physicians might have not prescribed the steroids. Considering this, the actual prescription rates of steroids might be higher than observed.

Our study has limitations for generalization [31]. First, this study analyzed insurance-covered medications prescribed in clinical practice, therefore non-covered medications were not included in the analysis. In particular, xylometazoline hydrochloride, the topical decongestant with the highest sales, could not be analyzed in this study because it is a non-reimbursable medicine. Accordingly, for decongestants, only systemic decongestants were investigated, and in this regard, generalizability is a drawback of this study. Also, we did not investigate antihistamines and topical decongestants sold as OTC preparations. This does not serve as a bias because this study aimed to investigate only the prescriptions of the clinicians. However, as OTC preparations are thought to have affected the prescription trend, the exact description of the factors related to the prescription trend remains a limitation. Further, allergen immunotherapy is a treatment emphasized in the guidelines and needs to be analyzed. However, since it is not covered by the national health insurance of South Korea, it could not be included in this study. In addition, there was a bias in the episode analysis of patients because yearly cross-sectional data were used. In particular, when analyzing first-choice prescriptions, if the patient’s prescription continued from the previous year, the prescription information of the previous year was not considered.

Nevertheless, to the best of our knowledge, the present study is significant because it is the first most extensive analysis on the long-term trends of medication prescriptions to treat AR. Furthermore, actual clinical decisions were analyzed from various perspectives with an analysis of a range of medication prescriptions and patterns. In particular, nationwide data representing the South Korean population were used, and all citizens and medical institutions are members of the Korean health insurance system as a regulatory requirement. Thus, the data were highly representative, and there were few limitations pertaining to the generalization of the study findings. Since there have been few analyses of AR prescription trends, the results of this study can be used to develop a clinical guideline in the future and can help confirm whether the guideline developed is clinically applicable.

Conclusions
This study revealed a decrease in the prescriptions of antihistamines, especially first-generation antihistamines, and an increase in the prescriptions of steroids and LTRAs for patients with AR in South Korea. Furthermore, the rate of prescription of combinations of antihistamines and steroids increased. However, this trend differed depending on patient characteristics, and the rate of increase in steroid prescriptions was relatively lower in patients aged 0–5 years and ≥ 65 years. It is expected that these results can serve as basic research data for clinicians and policymakers in the development and application of relevant guidelines.

Abbreviations
AR: Allergic rhinitis; LTRAs: Leukotriene receptor antagonists; ARIA: Allergic Rhinitis and its Impact on Asthma; HIRA-NPS: Health Insurance Review & Assessment Service National Patient Sample.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12948-021-00158-5.

Supplementary Material
Additional file 1. Supplemental materials.

Acknowledgements
Not applicable.

Authors’ contributions
JS, ESK, DL, and YJL planned and designed the study. ESK performed the statistical analysis and prepared tables and figures. HC and IHH performed the interpretation of the results. JS wrote the manuscript. All corresponding authors equally contributed to this work. All authors read and approved the final manuscript.

Funding
This study was supported by the Traditional Korean Medicine R&D program funded by the Ministry of Health & Welfare through the Korea Health Industry Development Institute (HB16C0009). The funding body had no role in designing the study; collecting, analyzing, and interpreting the data; and writing the manuscript.

Availability of data and materials
The Health Insurance Review & Assessment Service National Patient Sample (HIRA-NPS) is provided by the Health Insurance Service & Assessment Service in Korea. To protect privacy, access to the data is available only for certified researchers in South Korea.

Declarations
Ethics approval and consent to participate
Owing to the retrospective nature of this study, which utilized data with de-identified personal information, the Institutional Review Board of Jaseng Hospital of Korean Medicine in Seoul, Korea (JASENG 2020-10-012) granted an approval exemption.
Consent for publication
All authors approved the final version and provided consent for publication.

Competing interests
This study was supported by the Traditional Korean Medicine R&D program funded by the Ministry of Health & Welfare through the Korea Health Industry Development Institute (HI16C0009).

Author details
1 Jaseng Hospital of Korean Medicine, S36 Gangnam-daero, Gangnam-gu, Seoul 06110, Republic of Korea. 2 Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, 3F, 538 Gangnam-dae-ro, Gangnam-gu, Seoul 06110, Republic of Korea. 3 Department of Medical Science of Meridian, College of Korean Medicine, Graduate School, Kyung Hee University, 02453 Seoul, Republic of Korea. 4 Department of Ophthalmology, Otolaryngology, and Dermatology, College of Korean Medicine, Woo-Suk University, 55338 Jeonju, Republic of Korea.

Received: 14 July 2021 Accepted: 20 September 2021 Published online: 11 October 2021

References
1. Cruz AA. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. Geneva: World Health Organization; 2007.
2. Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U, Stewart A, Group IPTS. The International Study of Asthma and Allergies in Childhood (ISAAC) phase three: a global synthesis. Allergol Immunopatol. 2013;41:73–85.
3. Rate of being diagnosed with allergic rhinitis from clinicians. https://health.cdc.gov/ora/healthinfo/cls/privacy/visit/details.do?ctgrSn=39.
4. Vandenplas O, Vinnikov D, Blanc PD, Agache I, Bachert C, Bewick M, Cardell L-O, Cullinan P, Demoly P, Descatha A. Impact of rhinitis on work productivity: a systematic review. J Allergy Clin Immunol. 2018;127:4–86.
5. Craig TJ, McCarrn JL, Gurevich F, Davies MJ. The correlation between allergic rhinitis and sleep disturbance. J Allergy Clin Immunol. 2004;114:39–45.
6. Bousquet PJ, Demoly P, Devillier P, Mesbahi K, Bousquet J. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol. 2013;160:393–400.
7. Skoner DP. Complications of allergic rhinitis. J Allergy Clin Immunol. 2000;105:605–9.
8. Klimkiewicz J, Bachert C, Pfaar O, Becker S, Bieber T, Brehler R, Buhl R, Casper J, Chaker A, Czech W. ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergo J. Int. 2019;28:255–76.
9. Kim YH, Kim M-A, Yang H-J, Choi J-H, Kim D-K, Yoo Y, Lee B, Kim B-S, Kim W-Y, Kim JH, Park SY, Bae WY, Song K, Ynaeg M-S, Lee SM, Lee Y-M, Lee H-J, Cho J-H, Lee HM, Park Y. Clinical diagnostic guidelines for allergic rhinitis: medical treatment. J Korean Med Assoc. 2017;60:183–93.
10. Kim HK, Kim TH. Current trends in treatment of allergic rhinitis. J Korean Med Assoc. 2016;59:300–8.
11. De Blic J, Wahn U, Billard E, Alt R, Pujazon MC. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol. 2005;16:267–73.
12. Church M, Maurer M, Simons F, Bindlev-Jensen C, Van Cauwenberge P, Bousquet J, Holgate S, Zuberbier T. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy; 2010;65:459–66.
13. Simon FER, Simons KJ. H 1 antagonists: current status and future directions. World Allergy Organization Journal. 2008;1:145.
14. Ho V, Lounisien E, Jordens A, Aasbjerg K, Agache I, Alobid I, Bachert C, Boussery K, Campo P, Fokkens W. Benefits and harm of systemic steroids for short-and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clinical translational allergy. 2020;10:1–27.
15. Wilson AM, O’Byrne PM, Parameswarakan K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. The American Journal of Medicine. 2004;116:338–44.
16. Wheatley LM, Togias A. Allergic rhinitis. N Engl J Med. 2015;372:456–63.
17. Çobanoğlu B, Taskaleta E, Ural A, Cingi C. Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2013;13:203–8.
18. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schünemann HJ. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126:666–76.
19. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108:618–8.
20. Yilmaz O, Atintas D, Rondon C, Cingi C, Ogahan F. Effectiveness of montelukast in pediatric patients with allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2013;77:1922–4.
21. Details about the criteria and methods of reimbursement for the 2017–2021 issue. (Welfare MoHa ed.; 2017).
22. Miligkos M, Bannuru RR, Akofode H, Hoker SR, Schmid CH, Balk EM. Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis. Ann Intern Med. 2015;163:756–67.
23. Ferguson L, Futamura M, Vakirlis E, Kojima R, Sasaki H, Roberts A, Mori R. Leukotriene receptor antagonists for eczema. Cochrane Database System Rev. 2018;9:766.
24. Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35:1763–74.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.